

SEQUENCE LISTING

<110> Evotec NeuroSciences GmbH

<120> Diagnostic and Therapeutic Use of the human DAX-1 gene
and protein for neurodegenerative diseases

<130> 042327wo Me/FM

<140> PCT/EP2004/052684

<141> 2004-10-28

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 470

<212> PRT

<213> Homo sapiens

<400> 1

Met Ala Gly Glu Asn His Gln Trp Gln Gly Ser Ile Leu Tyr Asn Met
1 5 10 15

Leu Met Ser Ala Lys Gln Thr Arg Ala Ala Pro Glu Ala Pro Glu Thr
20 25 30

Arg Leu Val Asp Gln Cys Trp Gly Cys Ser Cys Gly Asp Glu Pro Gly
35 40 45

Val Gly Arg Glu Gly Leu Leu Gly Gly Arg Asn Val Ala Leu Leu Tyr
50 55 60

Arg Cys Cys Phe Cys Gly Lys Asp His Pro Arg Gln Gly Ser Ile Leu
65 70 75 80

Tyr Ser Met Leu Thr Ser Ala Lys Gln Thr Tyr Ala Ala Pro Lys Ala
85 90 95

Pro Glu Ala Thr Leu Gly Pro Cys Trp Gly Cys Ser Cys Gly Ser Asp
100 105 110

Pro Gly Val Gly Arg Ala Gly Leu Pro Gly Gly Arg Pro Val Ala Leu
115 120 125

Leu Tyr Arg Cys Cys Phe Cys Gly Glu Asp His Pro Arg Gln Gly Ser
130 135 140

Ile Leu Tyr Ser Leu Leu Thr Ser Ser Lys Gln Thr His Val Ala Pro
145 150 155 160

Ala Ala Pro Glu Ala Arg Pro Gly Gly Ala Trp Trp Asp Arg Ser Tyr
165 170 175

Phe Ala Gln Arg Pro Gly Gly Lys Glu Ala Leu Pro Gly Gly Arg Ala
180 185 190

Thr Ala Leu Leu Tyr Arg Cys Cys Phe Cys Gly Glu Asp His Pro Gln
195 200 205

Gln Gly Ser Thr Leu Tyr Cys Val Pro Thr Ser Thr Asn Gln Ala Gln
210 215 220

Ala Ala Pro Glu Glu Arg Pro Arg Ala Pro Trp Trp Asp Thr Ser Ser
225 230 235 240

Gly Ala Leu Arg Pro Val Ala Leu Lys Ser Pro Gln Val Val Cys Glu
245 250 255

Ala Ala Ser Ala Gly Leu Leu Lys Thr Leu Arg Phe Val Lys Tyr Leu
260 265 270

Pro Cys Phe Gln Val Leu Pro Leu Asp Gln Gln Leu Val Leu Val Arg
275 280 285

Asn Cys Trp Ala Ser Leu Leu Met Leu Glu Leu Ala Gln Asp Arg Leu
290 295 300

Gln Phe Glu Thr Val Glu Val Ser Glu Pro Ser Met Leu Gln Lys Ile
305 310 315 320

Leu Thr Thr Arg Arg Arg Glu Thr Gly Gly Asn Glu Pro Leu Pro Val
325 330 335

Pro Thr Leu Gln His His Leu Ala Pro Pro Ala Glu Ala Arg Lys Val
340 345 350

Pro Ser Ala Ser Gln Val Gln Ala Ile Lys Cys Phe Leu Ser Lys Cys
355 360 365

Trp Ser Leu Asn Ile Ser Thr Lys Glu Tyr Ala Tyr Leu Lys Gly Thr
370 375 380

Val Leu Phe Asn Pro Asp Val Pro Gly Leu Gln Cys Val Lys Tyr Ile
385 390 395 400

Gln Gly Leu Gln Trp Gly Thr Gln Gln Ile Leu Ser Glu His Thr Arg
405 410 415

Met Thr His Gln Gly Pro His Asp Arg Phe Ile Glu Leu Asn Ser Thr
420 425 430

Leu Phe Leu Leu Arg Phe Ile Asn Ala Asn Val Ile Ala Glu Leu Phe
435 440 445

Phe Arg Pro Ile Ile Gly Thr Val Ser Met Asp Asp Met Met Leu Glu
450 455 460

Met Leu Cys Thr Lys Ile
465 470

<211> 2022
<212> DNA
<213> *Homo sapiens*

<400> 2

```
<210> 3
<211> 23
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: primer for the
DAX-1 gene

<400> 3
taccaaqqaq tacqcctacc tca

23

<210> 4
<211> 20
<212> DNA

<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: primer for the
DAX-1 gene

<400> 4
cacgtccggg ttaaagagca

20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
cyclophilin B gene

<400> 5
actgaaggcac tacgggcctg

20

<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
cyclophilin B gene

<400> 6
agccgttgtt gtctttgcc

19

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
ribosomal protein S9 gene

<400> 7
ggtcaaattt accctggcca

20

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
ribosomal protein S9 gene

<400> 8
tctcatcaag cgtcagcagt tc 22

<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the beta-actin gene

<400> 9
tggaacggtg aaggtgaca 19

<210> 10
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the beta-actin gene

<400> 10
ggcaaggggac ttcctgtaa 19

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the GAPDH gene

<400> 11
cgtaggggt gtgaaccatg 20

<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the GAPDH gene

<400> 12
gctaaggcgt tggtggtgca g 21

<210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
transferrin receptor gene

<400> 13
gtcgctggtc agttcgtgat t

21

<210> 14
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for the
transferrin receptor gene

<400> 14
agcagttggc tgttgtacct ctc

23

<210> 15
<211> 1413
<212> DNA
<213> Homo sapiens

<400> 15
atggcgggcg agaaccacca gtggcagggc agcatcctct acaaactgct tatgagcgcg 60
aagcaaacgc gcgcggctcc tgaggctcca gagacgcggc tggatca gtgtggggc 120
tgttcgtgcg gcatgagcc cgggtgggc agagagggc tgctggcg gccaacgtg 180
gcgcctctgt accgctgctg ctttgcggt aaagaccacc cacggcaggc cagcatcctc 240
tacagcatgc tgacgagcgc aaagcaaacg tacgcggcac cgaaggcgcc cgaggcgacg 300
ctgggtccgt gctggggctg ttctgtgcggc tctgatcccgg ggttggcag agcggggctt 360
ccgggtggc ggccctgtgc actcctgtac cgctgctgt tttgtggta agaccacccg 420
cgccaggcga gcattcctta cagcttgctc actagctcaa agcaaacgcga cgtggctccg 480
gcagcgcggc aggcacgcgc agggggcgcg tgggtggacc gctcctactt cgcgcagagg 540
ccaggggtta aagaggcgtt accaggcggg cggccacgg cgctctgtt cgcgtctgc 600
ttttgcgttg aagaccaccc gcagcaggc agcaccctct actgcgtgcc cacgagcaca 660
aatcaagcgc aggcggctcc ggaggagcgg ccgagggccc cctgggtggaa cacctcctct 720
ggtgcgtgc ggccgggtggc gctcaagagt ccacaggtgg tctgcgaggc agcctcagcg 780
ggcctgttga agacgctgcg ctgcgtcaag tacttccccct gcttccagggt gctgccctg 840
gaccagcagc tgggtctggt gcgcaactgc tgggcgtccc tgctcatgt tgagctggcc 900
caggaccgt tgcagttcga gactgtggaa gtctcgagc ccagcatgt gcagaagatc 960
ctcaccacca ggcggcggg gaccggggc aacgagccac tgccctgtgcc cacgctgcag 1020
caccatttg caccggccggc ggaggccagg aaggtccccct ccgcctccca ggtccaagcc 1080
atcaagtgtt ttctttccaa atgctggagt ctgaacatca gtaccaagga gtacgcctac 1140
ctcaagggga ccgtgcttt taacccggac gtgcggggcc tgcagtgctggt gaagtacatt 1200
caggactcc agtggggaaac tcagcaaata ctcagtgaaac acaccaggat gacgcaccaa 1260
gggccccatg acagattcat cgaacttaat agtaccctt tcctgctgag attcatcaat 1320
gccaatgtca ttgctgaact gttttcagg cccatcatcg gcacagtcag catggatgat 1380
atgatgctgg aaatgctctg tacaagata taa 1413

Docket No.: 37998-237364
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Von Der Kammer et al.

Art Unit: Not Yet Assigned

Application No: 10/595,619

Examiner: Not Yet Assigned

Confirmation No: 3638

Filed: May 1, 2006

Atty. Docket No: 37998-237364

For: DIAGNOSTIC AND THERAPEUTIC USE
OF THE HUMAN DAX-1 GENE AND
PROTEIN FOR NEURODEGENERATIVE
DISEASES

Customer No:

26694

PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In order to comply with the duty of disclosure pursuant to 37 C.F.R. § 1.56, submitted herewith is a form listing the documents cited in the International Search Report of International

Application No. PCT/EP2004/053573. The relevance of each document is indicated in the International Search Report.

Copies of the documents are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237364. A duplicate copy of this paper is enclosed.

Dated: May 7, 2007

Respectfully submitted,

By Kavita B. Lepping
Kavita B. Lepping
Registration No.: 54,262
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

DC2/856087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/595,619-Conf. #3638
				Filing Date	May 1, 2006
				First Named Inventor	Heinz Von Der Kammer
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	37998-237364

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-2002/068815		06-06-2002	Edward R. McCabe et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Zanaria, Elena et al., "An unusual member of the nuclear hormone receptor superfamily responsibile for x-linked adrenal hypoplasia congenita," Nature, vol. 372, no. 6507, 1994, pgs. 635-641			
	CB	Guo, Weiwen et al., "Expression of DAX-1, the gene responsible of X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis," Biochemical and Molecular Medicine, vol. 56, no. 1, 1995, pgs. 8-13			
	CC	Kopp, Peter, "Targeted disruption of teh Ahch (Dax-1) gene: Knockout of old concepts," European Journal of Endocrinology, vol. 140, no. 4, April 1999, pgs. 291-292			
	CD	Eckey, Maren et al., "Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors," Molecular and Cellular Endocrinology, vol. 213, no. 1, 12/31/2003, pgs. 71-78			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/052684

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 G01N33/50 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/068815 A1 (MCCABE EDWARD R. B ET AL) 6 June 2002 (2002-06-06) abstract paragraphs '0013!, '0017!, '0018!, '0136! - '0149!; claims 8,14,20; example 3 -----	3,9
A	ZANARIA ELENA ET AL: "An unusual member of the nuclear hormone receptor superfamily responsible for x-linked adrenal hypoplasia congenita" NATURE (LONDON), vol. 372, no. 6507, 1994, pages 635-641, XP002339051 ISSN: 0028-0836 abstract page 638, column 2, paragraphs 2,3 ----- -/-	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 August 2005

22/08/2005

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Klee, B

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2004/052684

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>ECKEY MAREN ET AL: "Mixed lineage kinase 2 enhances trans-repression of Alien and nuclear receptors."</p> <p>MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 213, no. 1, 31 December 2003 (2003-12-31), pages 71-78, XP002339011 ✓</p> <p>ISSN: 0303-7207 abstract page 75, column 2, paragraph 2 - page 77, column 1, paragraph 5</p> <p>-----</p>	1-16
A	<p>GUO WEIWEN ET AL: "Expression of DAX-1, the gene responsible of X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism, in the hypothalamic-pituitary-adrenal/gonadal axis"</p> <p>BIOCHEMICAL AND MOLECULAR MEDICINE, vol. 56, no. 1, 1995, pages 8-13, ✓</p> <p>XP002339052 ISSN: 1077-3150 cited in the application abstract page 10, column 1, paragraph 4 - page 12, column 1, paragraph 1</p> <p>-----</p>	1-16
X	<p>KOPP PETER: "Targeted disruption of the Ahch (Dax-1) gene: Knockout of old concepts"</p> <p>EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 140, no. 4, April 1999 (1999-04), pages 291-292, XP002339200 ✓</p> <p>ISSN: 0804-4643 the whole document</p> <p>-----</p>	4,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/052684

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002068815 A1	06-06-2002	AU 6601096 A WO 9704810 A1	26-02-1997 13-02-1997